Det medfødte Immunforsvar og Det Enteriske Nervesystem Ved Crohns Sygdom
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Crohn Disease
- Sponsor
- Aalborg University Hospital
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- MxA expression
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
The study aims to explore the relationships between inflammation, nerve changes, and the expression of interferon-stimulated proteins in inflamed and non-inflamed bowel areas from patients with Crohn's disease. Crohn's disease is a chronic inflammatory condition with complex causes and mechanisms that remain uncertain despite extensive research.
Methods and Procedures This exploratory study utilizes tissue samples from a clinical biobank at Aalborg University Hospital. The samples are paraffin-embedded blocks from which tissue sections are prepared for immunohistochemical and histological staining. The study focuses on assessing the expression of interferon-stimulated proteins through optimized immunohistochemical staining methods, ensuring reproducibility via automated machines. The protein expressions are then analyzed qualitatively and semi-quantitatively and compared with structural changes in the bowel tissues.
Investigators
Christian Thomsen
MD
Aalborg University Hospital
Eligibility Criteria
Inclusion Criteria
- •Histological preparations (tissue samples) from patients with Crohn's disease who have undergone bowel resection at Aalborg University Hospital in the period from 2012 to 2023.
Exclusion Criteria
- •If the tissue material does not include the ileocecal region.
- •If the pathology report does not indicate that there is tissue material from both inflamed and non-inflamed areas.
- •If the patient has registered a prohibition against research in the Tissue Utilization Registry.
- •The selection of cases starts with the most recent (by date) and stops when 25 suitable cases are found.
Outcomes
Primary Outcomes
MxA expression
Time Frame: June 1 2024
Immunohistochemical Mxa expression
Secondary Outcomes
- Enterovirus positivity(June 1 2024)